Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Current therapies for Clostridioides difficile infection (CDI) (recurrent) fail to address the disrupted microbiome, which facilitates the germination of C. difficile spores into toxin-producing bacteria. SER-109 is an investigational microbiome therapeutic that consists of purified Firmicutes spores, aimed at treating recurrent C. difficile infection (1)
NCT03183128 - ECOSPOR III - SER-109 & Clostridioides difficile infection (CDI) (recurrent) is a randomized, double-blind, placebo-co…